ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2025
Advances in anti-inflammatory treatment of sepsis-associated acute respiratory distress syndrome.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Pathophysiology-guided biomarkers and therapeutics for precision trauma medicine in polytrauma with musculoskeletal injuries.Military Medical Research · 2026Review
- Correlation analysis of the expression levels of serum endothelial cell adhesion molecule-1 and sirtuin 1 protein in acute respiratory distress syndrome.Journal of medical biochemistry · 2026Article
- Tetrahedral DNA Nanostructure-Based Biomimetic Nanovesicles Attenuate Sepsis-Associated ARDS by Suppressing Glycolysis via the BMAL1/PFKFB3 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Elucidating the Mechanism of Fusu Agent Against Sepsis-Induced Acute Respiratory Distress Syndrome via an Integrated Approach Combining Network Pharmacology, Molecular Dynamics Simulations, and Experimental Validation.Journal of inflammation research · 2026Article
- Prognostic nutritional index, Naples prognostic score and Osaka prognostic score as predictors of acute respiratory distress syndrome in non-diabetes mellitus patients with sepsis: a loss of predictive efficacy of NPS and OPS in diabetes mellitus cohorts.Frontiers in endocrinology · 2026Article
- Mitochondrial dysfunction in sepsis-induced immunoparalysis: from immune-cell metabolic reprogramming to clinical biomarkers.Frontiers in immunology · 2026Review
- Thirty-five years of evolving inflammatory paradigms in sepsis (1991-2025): a comprehensive mapping of immune dysregulation research, anti-inflammatory targets, and translational barriers.Frontiers in immunology · 2026Article
- Genetic variation at the IL-18-137C>G is associated with poor sepsis prognosis and enhanced inflammatory responses: a multicenter hospital-based study.Frontiers in genetics · 2026Article
- The ZFP36-FTO axis is a key regulator of macrophage activation and a druggable therapeutic target of sepsis.iScience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sepsis is characterized by a dysregulated host response to infection, leading to organ dysfunction and associated with significant morbidity and mortality, posing a critical challenge to global public health. Among its complications, sepsis frequently causes acute respiratory distress syndrome (ARDS), which has a high incidence and mortality rate, particularly in intensive care units (ICUs). Currently, the management of sepsis-induced ARDS is largely limited to supportive care, as no specific pharmacological treatments are available. The progression of sepsis to ARDS is driven by severe inflammation and cytokine storms, highlighting the importance of anti-inflammatory therapies as a primary treatment focus. We summarize conventional drugs and emerging treatments targeting excessive inflammatory responses in sepsis-associated ARDS, reviewing progress in basic research and clinical trials. Additionally, we discuss current research challenges to propose future directions for anti-inflammatory treatments, aiming to develop highly effective drugs with better clinical translation potential.
Indexed as
Identifiers
40298991What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.